Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Drug

Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038

Fineline Cube Jan 16, 2023

Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...

Company Deals

Eyougene Raises Hundreds of Millions in Series B Funding for Expansion

Fineline Cube Jan 13, 2023

Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has...

Company Deals

LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions”...

Company Deals

Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has...

Company Drug

Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study

Fineline Cube Jan 13, 2023

China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...

Company Deals

Cii Tech Secures Tens of Millions in Pre-Series A Funding for Mass Spectrometry

Fineline Cube Jan 13, 2023

China Innovation Instrument (Cii Tech), a life sciences instrument maker based in Ningbo, has reportedly...

Company Deals

TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline

Fineline Cube Jan 13, 2023

TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of...

Company Drug

Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma

Fineline Cube Jan 13, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...

Company Drug

Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study

Fineline Cube Jan 13, 2023

Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...

Company

Porton Pharma Solutions to Invest EUR 50 Million in Slovenia Bio-Industry Park

Fineline Cube Jan 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a...

Company Digital

ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions

Fineline Cube Jan 13, 2023

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced...

Company Deals

Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US

Fineline Cube Jan 13, 2023

US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc.,...

Company Drug

Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management

Fineline Cube Jan 13, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment

Fineline Cube Jan 13, 2023

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...

Policy / Regulatory

China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs

Fineline Cube Jan 13, 2023

The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...

Company

Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization

Fineline Cube Jan 12, 2023

Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several...

Company Drug Legal / IP

MSD China to Take Legal Action Against Market Infringement of Molnupiravir

Fineline Cube Jan 12, 2023

Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...

Company Deals

Med Vision Secures Series A+ Funding to Expand Digital Therapy Portfolio

Fineline Cube Jan 12, 2023

Med Vision, a Hangzhou-based digital therapy specialist, has reportedly raised “tens of millions” of renminbi...

Company Drug

Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution

Fineline Cube Jan 12, 2023

China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...

Company Deals

Bioantibody Bio Raises RMB 100 Million in Series A Funding Round

Fineline Cube Jan 12, 2023

Bioantibody Biotechnology Co., Ltd, a Nanjing-based in vitro diagnostics (IVD) and biologic company, has reportedly...

Posts pagination

1 … 587 588 589 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.